Satralizumab

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Conditions

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Trial Timeline

Aug 30, 2022 → Dec 31, 2028

NCT ID

NCT05271409

About Satralizumab

Satralizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05271409. Target conditions include Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

What happened to similar drugs?

3 of 14 similar drugs in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) were approved

Approved (3) Terminated (1) Active (11)

✅Alemtuzumab infusionSanofiApproved

✅IgPro10CSLApproved

✅Efgartigimod PH20 SCArgenxApproved

🔄Fingolimod + Placebo ComparatorNovartisPhase 3

🔄Riliprubart Prefilled Pen (PFP)SanofiPhase 3

🔄Riliprubart + Placebo + Riliprubart + PlaceboSanofiPhase 3

🔄riliprubart + Placebo + riliprubart + Placebo + IVIg + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05503264	Phase 3	Recruiting	Sep 27, 2022	Dec 14, 2029	NMDAR Autoimmune Encephalitis
NCT05271409	Phase 3	Recruiting	Aug 30, 2022	Dec 31, 2028	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
NCT04963270	Phase 3	Terminated	Oct 19, 2021	Sep 2, 2024	Generalized Myasthenia Gravis

Competing Products

20 competing products in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

See all competitors

Product	Company	Stage	Hype Score
Fingolimod + Placebo Comparator	Novartis	Phase 3	40
KITE-363 + Fludarabine + Cyclophosphamide	Gilead Sciences	Phase 1	36
Recombinant human acid sphingomyelinase	Sanofi	Phase 1	29
Olipudase alfa	Sanofi	Pre-clinical	26
placebo (saline) + Olipudase alfa	Sanofi	Phase 2/3	38
GZ402665	Sanofi	Phase 2	35
Olipudase alfa	Sanofi	Phase 1/2	32
SAR445088 (IV) + SAR445088 (SC)	Sanofi	Phase 2	35
olipudase alfa (GZ402665)	Sanofi	Pre-clinical	26
Riliprubart Prefilled Pen (PFP)	Sanofi	Phase 3	47
Riliprubart + Placebo + Riliprubart + Placebo	Sanofi	Phase 3	47
Alemtuzumab infusion	Sanofi	Approved	35
rhASM + rhASM + rhASM + rhASM + rhASM	Sanofi	Phase 1	21
riliprubart + Placebo + riliprubart + Placebo + IVIg + Placebo	Sanofi	Phase 3	47
Intravenous Immunoglobulin	CSL	Pre-clinical	26
IgPro10	CSL	Approved	50
Immune Globulin Subcutaneous (Human)	CSL	Pre-clinical	26
IgPro20	CSL	Phase 3	40
Hizentra	CSL	Pre-clinical	33
10% liquid formulation of human immunoglobulin	CSL	Phase 3	40